Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes
about
Homotropic allosteric regulation in monomeric mammalian glucokinaseThe hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic ratsThe active conformation of human glucokinase is not altered by allosteric activatorsInsights into Mechanism of Glucokinase ActivationMolecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinaseA panel of diverse assays to interrogate the interaction between glucokinase and glucokinase regulatory protein, two vital proteins in human diseaseSmall molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humansA phospho-BAD BH3 helix activates glucokinase by a mechanism distinct from that of allosteric activatorsOrder-disorder transitions govern kinetic cooperativity and allostery of monomeric human glucokinaseGlucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver diseaseS 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.Strain analysis of protein structures and low dimensionality of mechanical allosteric couplings.Small-Molecule Allosteric Activation of Human Glucokinase in the Absence of Glucose.Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.Liver glucokinase: An overview on the regulatory mechanisms of its activity.Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus.Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes.Discontinued drugs in 2012: endocrine and metabolic.Drug discovery alliances in India--indications, targets, and new chemical entities.Glucokinase activators.Molecular targeting of the GK-GKRP pathway in diabetes.One-pot synthesis of new (1,3-thiazolo[5,4-b]pyridin-2-yl)benzenediols and their antiproliferative activities against human cancer cell lines.Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat.Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 DiabetesModulation of glucokinase by glucose, small-molecule activator and glucokinase regulatory protein: steady-state kinetic and cell-based analysis.The use of docking-based comparative intermolecular contacts analysis to identify optimal docking conditions within glucokinase and to discover of new GK activators.Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes.
P2860
Q26852900-DFC80C1A-1C83-4A79-A717-51A67218D250Q27333171-804B6FA1-1639-4F4A-959F-2BF0309B88E6Q27675665-3165ADEF-1BD2-4E3B-B0A0-D190A32F5F8FQ27677010-1908A5B1-7608-4A40-969C-EF00A4817984Q27678490-34908F4D-1EFE-467C-8E1B-FAEC5083BC12Q28539913-F9A9B59E-38C2-40C8-B137-244C20E76851Q28576077-74940418-184B-418D-806F-F94B12476BC0Q33855651-7CB7557B-D56E-47A7-B54B-BA11B647FA96Q34524540-B15C88A1-9E97-4E00-B687-0541793CCF8FQ35809618-54411F47-D42C-492C-8C56-6CF4F44FD032Q36965883-21834B30-3573-4485-89F5-8DE45CD0D3F8Q37322944-DAF55A75-E88A-49BE-B1FF-3DB68D0BAE8BQ37342791-390B0EAF-017B-4511-B8ED-98ADAB1CDD02Q37665590-4249F8F2-A9F8-4565-A64E-AE1BEF7E28DEQ37833579-AB871FBB-0D48-4A16-8517-FA30215BE714Q38069508-EABB8297-7F50-4062-AFE4-1DF4E8F26C06Q38071706-ECEE8EE1-F201-40C6-83C0-474C1304FEC6Q38130293-F2A157ED-1AFE-4FF2-A68A-3AB7B8868AA4Q38153661-DD9CA09A-41FF-4676-9941-6ED59620CA6CQ38162928-6173C31D-435B-48E5-8EF3-BFDA57614041Q38260964-46BCEEB7-30DA-4C65-9E05-2FE3CB731AB5Q39410730-9A9DC592-BFF5-4F05-BFDF-CFC2E7E9F131Q39414202-E5179EE4-A0EB-4DE9-80F6-9F15814D2069Q39771412-51326925-121C-4D36-888B-317C2D8F158AQ42623211-708944E5-D480-4632-8D21-248C8164D92FQ51103643-6516D36C-F1F8-4E11-9F69-3DD5EE49F0C1Q51107449-46DEC522-C134-4AB0-9B67-45A3F449154C
P2860
Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Investigation of functionally ...... e treatment of type 2 diabetes
@ast
Investigation of functionally ...... e treatment of type 2 diabetes
@en
Investigation of functionally ...... e treatment of type 2 diabetes
@nl
type
label
Investigation of functionally ...... e treatment of type 2 diabetes
@ast
Investigation of functionally ...... e treatment of type 2 diabetes
@en
Investigation of functionally ...... e treatment of type 2 diabetes
@nl
prefLabel
Investigation of functionally ...... e treatment of type 2 diabetes
@ast
Investigation of functionally ...... e treatment of type 2 diabetes
@en
Investigation of functionally ...... e treatment of type 2 diabetes
@nl
P2093
P356
P1476
Investigation of functionally ...... e treatment of type 2 diabetes
@en
P2093
Alokesh Duttaroy
Bethany A Dale
Brian Vash
Gregory R Bebernitz
Herbert F Schuster
Irene St Denny
Jiaping Gao
Jinsheng Liang
Louise C Kirman
Melissa S Grondine
P304
P356
10.1021/JM900839K
P407
P577
2009-10-08T00:00:00Z